Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-7.87 Insider Own34.92% Shs Outstand17.61M Perf Week-3.37%
Market Cap7.53M Forward P/E- EPS next Y-0.86 Insider Trans0.00% Shs Float8.67M Perf Month-35.10%
Income-144.90M PEG- EPS next Q-0.24 Inst Own17.09% Short Float0.12% Perf Quarter-59.96%
Sales0.00M P/S- EPS this Y82.97% Inst Trans-9.72% Short Ratio0.17 Perf Half Y-78.77%
Book/sh1.62 P/B0.35 EPS next Y22.17% ROA-110.92% Short Interest0.01M Perf Year-84.74%
Cash/sh0.40 P/C1.41 EPS next 5Y- ROE-144.22% 52W Range0.34 - 4.40 Perf YTD-68.98%
Dividend Est.- P/FCF- EPS past 5Y- ROI-449.66% 52W High-87.17% Beta97.98
Dividend TTM- Quick Ratio2.78 Sales past 5Y0.00% Gross Margin- 52W Low66.06% ATR (14)0.14
Dividend Ex-Date- Current Ratio2.78 EPS Y/Y TTM-570.82% Oper. Margin0.00% RSI (14)40.28 Volatility17.52% 22.41%
Employees7 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price6.50
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-328.89% Payout- Rel Volume0.19 Prev Close0.59
Sales Surprise- EPS Surprise-596.30% Sales Q/Q- EarningsFeb 28 AMC Avg Volume57.99K Price0.56
SMA20-7.51% SMA50-41.12% SMA200-73.83% Trades Volume10,901 Change-4.31%
Date Action Analyst Rating Change Price Target Change
Jul-18-22Resumed Oppenheimer Outperform $26
Mar-07-22Initiated H.C. Wainwright Buy $32
Sep-21-21Initiated Oppenheimer Outperform $30
Sep-02-21Initiated B. Riley Securities Buy $40
Aug-19-21Initiated Cantor Fitzgerald Overweight $35
Feb-28-24 05:10PM
Jan-04-24 08:00AM
Nov-28-23 04:01PM
Nov-06-23 08:01AM
Sep-29-23 08:00AM
08:00AM Loading…
Sep-20-23 08:00AM
Sep-05-23 08:00AM
Aug-30-23 08:00AM
Jul-31-23 04:05PM
Jun-26-23 08:00AM
Jun-05-23 08:00AM
Jun-01-23 08:00AM
Apr-26-23 05:00PM
Mar-07-23 08:00AM
Mar-01-23 08:00AM
04:05PM Loading…
Feb-27-23 04:05PM
Feb-15-23 08:00AM
Nov-29-22 04:43PM
Nov-10-22 09:00AM
Nov-08-22 08:00AM
Sep-14-22 08:39AM
Sep-08-22 08:00AM
Aug-29-22 08:00AM
Aug-18-22 08:00AM
Aug-01-22 09:10AM
Jul-20-22 09:00AM
Jul-06-22 04:05PM
Jun-06-22 08:00AM
Apr-25-22 08:00AM
10:00AM Loading…
Apr-13-22 10:00AM
Mar-31-22 08:00AM
Mar-09-22 09:00AM
Feb-24-22 05:43PM
Feb-15-22 08:00AM
Jan-05-22 08:00AM
Nov-23-21 08:00AM
Nov-22-21 04:53PM
Nov-15-21 08:00AM
Nov-10-21 08:00AM
Oct-26-21 10:13AM
Sep-10-21 08:00AM
Aug-30-21 08:00AM
Aug-12-21 08:00AM
Aug-05-21 08:00AM
Jul-28-21 08:00AM
Jun-29-21 09:00AM
Jun-24-21 09:00AM
Jun-23-21 04:10PM
Jun-02-21 08:30AM
Apr-16-21 09:00AM
Apr-08-21 09:00AM
Mar-25-21 09:00AM
Mar-04-21 08:00AM
Mar-02-21 08:00AM
Portage Biotech, Inc. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.